Form 8-K

8-K — PetVivo Holdings, Inc.

Accession: 0001493152-26-043639

Filed: 2026-09-22

Period: 2026-09-22

CIK: 0001512922

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001512922

2026-09-22

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

September

22, 2026

Date

of Report (Date of earliest event reported)

PETVIVO

HOLDINGS, INC.

(Exact

name of registrant as specified in its charter)

Nevada

001-40715

99-0363559

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

5151

Edina Industrial Blvd.

Suite

575

Edina,

Minnesota

55439

(Address

of principal executive offices)

(Zip

Code)

(952)

405-6216

Registrant’s

telephone number, including area code

Check

the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of

the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(g) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

PETV

OTCQX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

Resignation

of Diane Levitan

Effective

September 22, 2026, Diane Levitan resigned as a member of the Board of Directors (the “Board”) of PetVivo Holdings, Inc.,

a Nevada corporation (the “Company”). Dr. Levitan’s resignation was not the result of any disagreement with the Company

on any matter relating to the Company’s operations, policies or practices. The Board expresses its appreciation to Dr. Levitan

for her leadership, guidance and contributions during her tenure on the Board.

Appointment

of Jaime K. Pickett

Effective

September 22, 2026, the Board appointed Jaime K. Pickett as a director of the Company to fill the vacancy created by Dr. Levitan’s

resignation, thereby maintaining the size of the Board at six directors. Dr. Pickett will serve until the next annual meeting of shareholders

and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.

Dr.

Pickett is a veterinary healthcare executive, entrepreneur, multi-unit franchisee and board leader with more than 20 years of experience

spanning animal health, multi-site operations, corporate strategy, business development, clinical innovation, product commercialization

and organizational growth. She currently serves as Chief Medical Officer of EQUUSIR USA and as Advising Chief Medical Officer and a board

member of Alexander International Innovations, where she provides clinical, regulatory, commercialization and strategic guidance for

emerging medical and animal-health technologies. She also serves on the Board of Chief Veterinary Medical Officers, a professional organization

of senior veterinary executives, and is a Scenthound multi-unit franchisee.

From

2023 to 2026, Dr. Pickett held executive leadership roles with Hannah Pet Hospitals, including Chief Executive Officer, President, board

member and Chief Strategy Officer. From 2017 to 2022, she served as Chief Veterinary Officer and Senior Vice President of Pet Paradise

and as Chief Operating Officer of its subsidiary, NewDay Veterinary Care. In these executive leadership roles, she led veterinary and

operational strategy across more than 55 pet resorts and veterinary hospitals in over 15 states, directed teams of more than 100 veterinary

professionals, and was instrumental to the organization’s strong enterprise revenue. Her experience also includes veterinary practice

ownership, multi-site expansion, mergers and acquisitions evaluation, and telehealth implementation.

Dr.

Pickett earned her Doctor of Veterinary Medicine from the University of Florida College of Veterinary Medicine, an MBA from St. George’s

University and a Bachelor of Arts from Johns Hopkins University, with minors in Psychology and Computer Science. She also completed the

Global C-Suite Program through Wharton Executive Education at the University of Pennsylvania. Her governance and professional service

include service on the Board of Directors of The Doorways and nine years on the University of Florida College of Veterinary Medicine

Admissions Committee. She is a lifetime member of the University of Florida College of Veterinary Medicine Dean’s Circle of Excellence

and a member of the American Veterinary Medical Association.

Dr.

Pickett’s extensive veterinary healthcare and executive leadership experience, together with her background in multi-site operations,

corporate strategy, business development and animal-health technology commercialization, were material factors in the Board’s determination

that she is qualified to serve as a director of the Company.

Dr.

Pickett will initially serve as a non-employee director and receive compensation consistent with that of the Company’s other non-employee

directors, prorated for her period of service. The Company’s non-employee director compensation program is described in its Current

Report on Form 8-K filed with the Securities and Exchange Commission on October 8, 2025. Her compensation for Board service may be adjusted

by the Board in connection with any subsequent employment by the Company or one of its subsidiaries.

There

are no arrangements or understandings between Dr. Pickett and any other persons pursuant to which she was selected as a director of the

Company and there are no transactions or proposed transactions in which Dr. Pickett has a direct or indirect interest requiring disclosure

under Item 404(a) of Regulation S-K or Item 5.02(d) of Form 8-K. Dr. Pickett does not have any family relationship with any of the Company’s

directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer.

ther time, Dr. Pickett has not been appointed to any committees.

The

press release announcing her appointment is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

99.1

104

Press Release dated September 22, 2026

Cover

Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the

undersigned hereunto duly authorized.

PETVIVO

HOLDINGS, INC.

Date:

September 22, 2026

By:

/s/

John Lai

Name:

John

Lai

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

5151

Edina Industrial Blvd., Suite 575, Minneapolis, MN 55439 | (952) 405-6216 | www.petvivo.com

PRESS

RELEASE:

Jaime

Pickett Joins PetVivo Holdings, Inc. Board of Directors

MINNEAPOLIS, MN, US, September 22, 2026 —

PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”), an emerging biomedical device company focused on the commercialization

of innovative medical devices and therapeutics for companion animals, today announced the appointment of Jaime K. Pickett, DVM, MBA,

to its Board of Directors, effective September 22, 2026.

“We

are pleased to welcome Dr. Jaime Pickett to PetVivo’s Board of Directors,” said John Lai, Chief Executive Officer of PetVivo

Holdings, Inc. “Jaime brings a valuable combination of veterinary expertise, executive leadership and experience growing veterinary

care organizations. Her understanding of clinical practice, hospital operations and animal-health technology will provide an important

perspective as we work to expand product adoption, strengthen relationships with veterinarians and pursue opportunities for sustainable

growth.”

Dr.

Pickett is a veterinary healthcare executive, entrepreneur and board leader with more than 20 years of experience in animal health, multi-site

operations, corporate strategy, business development and product commercialization. She currently serves as Chief Medical Officer of

EQUUSIR USA and as Advising Chief Medical Officer and a board member of Alexander International Innovations, providing clinical, regulatory,

commercialization and strategic guidance for emerging medical and animal-health technologies. She also serves on the Board of Chief Veterinary

Medical Officers and is a Scenthound multi-unit franchisee.

From

2023 to 2026, Dr. Pickett held executive leadership roles with Hannah Pet Hospitals, including Chief Executive Officer, President, board

member and Chief Strategy Officer. From 2017 to 2022, she served as Chief Veterinary Officer and Senior Vice President of Pet Paradise

and as Chief Operating Officer of its subsidiary, NewDay Veterinary Care. In these executive leadership roles, she led veterinary and

operational strategy across more than 55 pet resorts and veterinary hospitals in over 15 states, directed teams of more than 100 veterinary

professionals, and was instrumental to the organization’s strong enterprise revenue. Her experience also includes veterinary practice

ownership, multi-site expansion, mergers and acquisitions evaluation, and telehealth implementation.

Dr.

Pickett earned her Doctor of Veterinary Medicine from the University of Florida College of Veterinary Medicine, an MBA from St. George’s

University and a Bachelor of Arts from Johns Hopkins University. She also completed the Global C-Suite Program through Wharton Executive

Education at the University of Pennsylvania. She is a member of the American Veterinary Medical Association and served for nine years

on the University of Florida College of Veterinary Medicine Admissions Committee.

“I

am excited to join PetVivo’s Board and contribute both a veterinarian’s perspective and my experience building and leading

animal-health businesses,” said Dr. Pickett. “Bringing new technologies into veterinary practice requires an understanding

of clinical needs, practice operations and the support veterinary teams need to evaluate and adopt them. I look forward to working with

John and the team to help advance PetVivo’s commercial strategy, strengthen connections with the veterinary community and create

long-term value for shareholders.”

Dr.

Pickett fills the vacancy created by Diane Levitan’s resignation, effective September 22, 2026. The Board thanks Dr. Levitan for

her leadership, guidance and contributions during her tenure. Following these changes, the Board continues to consist of six directors.

About

PetVivo Holdings, Inc.

PetVivo

Holdings, Inc. (OTCQX: PETV), together with its subsidiaries PetVivo Animal Health, Inc., Somatrix Technologies, Inc. and PetVivo AI,

Inc., is an emerging biomedical device company focused on the development, manufacturing, commercialization and licensing of innovative

medical devices, biomaterials and therapeutics for animal and human health. The Company’s strategy is to leverage its proprietary

technologies, intellectual property and scientific expertise to develop and commercialize products addressing unmet needs across veterinary

and human medicine.

PetVivo

has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve issued and pending patents and six trade

secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product,

SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness

and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.

Company

Contact

John

Lai, CEO

PetVivo

Holdings, Inc.

Contact

Tel

(952) 405-6216

Forward-Looking

Statements

The

foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements”

within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended.

Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation

the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,”

“will,” “expect,” “project,” “estimate,” “anticipate,” “plan,”

“believe,” “potential,” “should,” “continue” or the negative versions of those words

or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements

are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties

and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the

Company’s Annual Report on Form 10-K for the year ended March 31, 2026 and other periodic and current reports filed with the Securities

and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking

statements, whether as a result of new information, future events or otherwise.

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (61314 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 4

Binary file (18984 bytes)

Download ex99-1_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.3

Cover

Sep. 22, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 22, 2026

Entity File Number

001-40715

Entity Registrant Name

PETVIVO

HOLDINGS, INC.

Entity Central Index Key

0001512922

Entity Tax Identification Number

99-0363559

Entity Incorporation, State or Country Code

Entity Address, Address Line One

5151

Edina Industrial Blvd.

Entity Address, Address Line Two

Suite

575

Entity Address, City or Town

Edina

Entity Address, State or Province

Entity Address, Postal Zip Code

55439

City Area Code

(952)

Local Phone Number

405-6216

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

PETV

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration